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In a phase II trial, we evaluated chlorambucil and rituximab (CLB-R) as first-line induction treatment with or
without R as maintenance for elderly chronic lymphocytic leukemia (CLL) patients. Treatment consisted of
eight 28-day cycles of CLB (8 mg/m2/day, days 1–7) and R (day 1 of cycle 3, 375 mg/m2; cycles 4–8, 500 mg/
m2). Responders were randomized to 12 8-week doses of R (375 mg/m2) or observation. As per intention-to-
treat analysis, 82.4% (95% CI, 74.25–90.46%) of 85 patients achieved an overall response (OR), 16.5% a
complete response (CR), 2.4% a CR with incomplete bone marrow recovery. The OR was similar across Binet
stages (A 86.4%, B 81.6%, and C 78.6%) and age categories (60–64 years, 92.3%; 65–69, 85.2%; 70–74, 75.0%;
75, 81.0%). CLB-R was well tolerated. After a median follow-up of 34.2 months, the median progression-free
survival (PFS) was 34.7 months (95% CI, 33.1–39.5). TP53 abnormalities, complex karyotype, and low CD20
gene expression predicted lack of response; SF3B1 mutation and BIRC3 disruption low CR rates. IGHV
mutations significantly predicted PFS. R maintenance tended towards a better PFS than observation and
was safe and most beneficial for patients in partial response and for unmutated IGHV cases. CLB-R
represents a promising option for elderly CLL patients.
Am. J. Hematol. 89:480–486, 2014. VC 2014 Wiley Periodicals, Inc.
 Introduction
Over 40% of patients with chronic lymphocytic leukemia (CLL) are diagnosed at 75 years and over 25% at 65–74 years [1]. Elderly patients
have been consistently underrepresented in clinical trials, as age-related comorbidities may violate inclusion criteria [2].
Current standard of care for physically fit patients with untreated CLL is fludarabine, cyclophosphamide, and rituximab (FCR) [3], which indu-
ces the longest progression-free survival (PFS) and overall survival (OS) [4]. Although in the CLL8 trial no difference was noted in terms of
response and PFS, patients >65 years showed significantly higher rates of grade 3–4 hematologic toxicity and infections compared to younger
patients and no advantage in OS due to FCR [4]. Moreover, only 10–11% of patients >70 years entered each arm, underlying that elderly CLL are
often ineligible for fludarabine-containing therapies [4,5].
Additional Supporting Information may be found in the online version of this article.
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Chlorambucil (CLB) remains therefore a widely used first-line
treatment for such patients [3], but has limited effectiveness as mono-
therapy, with overall response (OR) rates up to 75%, but uncommon
complete responses (CRs) and short PFS [6–9]. Management of
elderly patients has remained a primary unmet need until recently,
when evidence-based therapeutic strategies exploring the association
between CLB and anti-CD20 monoclonal antibodies are being
reported [10–12].
Several biologic properties of CLL cells allow patient stratification
into risk categories that predict PFS and OS [4,13]. The impact of
novel gene mutations (NOTCH1, SF3B1, and BIRC3) on CLL treat-
ment outcome is currently under investigation.
We conducted a single-arm, phase II, open-label, multicenter study
of CLB plus R (CLB-R) as induction, followed by a randomized main-
tenance with R or observation (protocol ML21445), to determine if
CLB-R is feasible and beneficial as first-line treatment for elderly CLL
patients. Treatment outcome has been correlated with biologic param-
eters, including gene expression profiling (GEP) and novel mutations.
Furthermore, we explored the impact of R as maintenance treatment.
 Methods
Patients. The study included patients aged >65 years (or 60–65 years not eligi-
ble for fludarabine-based regimens) with previously untreated CLL (Binet stage A
or B with active disease or stage C), diagnosed according to the International
Workshop on CLL (iwCLL) update of the National Cancer Institute (NCI) 1996
guidelines [14]. Exclusion criteria included: history of other malignancies within 2
years prior to study entry or severe cardiac disease, comorbidities requiring >1
month use of systemic corticosteroids, creatinine clearance <50 mL/min, or trans-
formation to aggressive B-cell malignancy.
Study design and treatment. This study was designed to assess the efficacy and
safety of CLB-R as induction therapy and explore the role of a maintenance phase
with R or observation in responders. The primary endpoint was OR at the end of
induction. Secondary endpoints included CR, CR with incomplete bone marrow
recovery (CRi), and partial response (PR) at the end of the induction and OR, CR,
and PR at the end of the maintenance phase, immunophenotypic CR, molecular
CR, event-free survival (EFS), PFS, time to new CLL treatment (TTNT) or death,
and OS, safety of the induction phase and the R maintenance arm, response and
survival endpoints in biologically defined subgroups.
Response assessment was performed 2 months after induction completion. Defi-
nition of response was based on iwCLL criteria updating the NCI 1996 guidelines
[14]. The first dose of R maintenance was scheduled 3 months after the last induc-
tion cycle in randomized patients.
The study was approved by the Institutional Review Board of the coordinating
center and by the ethics committees of the 19 participating centers. All patients
provided written informed consent. The trial was conducted in respect of the Hel-
sinki Declaration, of Good Clinical Practice, and of applicable national regulations.
The study period was from October 2008 to January 2013.
Treatment is detailed in Fig. 1a. Treatment modifications in case of cytopenia or
adverse event (AE) are specified in Supporting Information.
Biologic work-up, including minimal residual disease (MRD) in CR patients, is
detailed in the Supporting Information [15–22].
Statistical analysis. Based on an a-level of 0.05 to show a significant difference
with respect to the primary endpoint of OR rate after the induction phase, the
planned sample size has estimated from 72 to 94 subjects to obtain a power at least
of 80% and a maximum of 90%.
The calculation of the sample size was based on the following assumptions:
– 0.65 OR proportion in null hypothesis.
– 0.80 OR proportion expected under alternative hypothesis.
Considering a 20% of non-evaluable subjects, from 90 to 118 subjects should
have been included in the study.
Statistical testing was conducted at the two-sided a5 0.05 level and two-sided
95% confidence intervals (CI) were used. To test the null hypothesis that the res-
ponders proportion was equal to 0.65 (H0: pt5 0.65), the binomial distribution
with the normal approximation was used (two-sided; a5 0.05). A two-sided v2
test and two-sided 95% confidence limits for response were used. Multivariate
logistic regression and univariate analyses assessed the impact of biologic parame-
ters on response rates. The Kaplan–Meier approach was used for time-related var-
iables estimates. Estimates for the median time-to-event and the corresponding
two-sided 95% CI were made together with the estimates for the other quartiles
and the range. Multivariate Cox regression analysis assessed the impact of prog-
nostic factors on survival endpoints and the impact of treatment group and prog-
nostic factors on survival endpoints on the randomized population (see
Supporting Information).
 Results
Patients’ characteristics
Ninety-seven patients entered the induction phase (safety popula-
tion) and 85 received 1 dose of R (intention-to-treat, ITT popula-
tion). Upon induction completion, 34 patients were randomized to R
maintenance and 32 to observation (Fig. 1b). Table I summarizes the
characteristics of the ITT and the maintenance randomized population.
In the ITT population, the median age was 70 years (range: 61–
84). Forty-four patients (51.8%) had 1 documented comorbidity at
baseline: 6/13 patients aged 60–64 years (46.1%), 12/27 aged 65–69
(44.4%), 11/24 aged 70–74 (45.8%), 12/17 aged 75–79 (70.5%) and 3/
4 aged 80 (75%).
Cytogenetic analysis using immunostimulatory CpG-oligonucleotide
DSP30 plus interleukin-2 [16] identified 12 cases with complex karyo-
types—that is, the presence of three or more cytogenetic aberrations in
the same clone—5 of which devoid of 17p2/11q2.
Induction efficacy
The OR rate in the ITT population (N5 85) was 82.4% (95% CI,
74.25–90.46%, n5 70), with 16.5% (n5 14) CR, 2.4% (n5 2) CRi,
60.0% (n5 51) PR, and 3.5% (n5 3) nodular PR. The OR rate was
similar across Binet stages—A, 86.4%; B, 81.6%; C, 78.6%—and age
categories—60–64 years, 92.3%; 65–69 years, 85.2%; 70–74 years,
75.0%; 75 years, 81.0%. Two of four patients 80 years responded
to induction. CR was achieved in 27.3% Binet stage A, 10.2% stage B,
and 21.4% stage C patients. Upon induction completion, cytometric
MRD on 14/16 CR/CRi patients showed a median of 0.02% residual
Figure 1. Treatment and patients flow. (a) Drug doses, schedules, and therapy scheme. CR5 complete response; CRi5 complete response with incom-
plete bone marrow recovery; PR5partial response. (b) CONSORT diagram. Summary of patients flow during the study.
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CLL cells (range 0–4.8%) on peripheral blood (PB), with undetectable
CLL in two cases. Bone marrow (BM) cytometric MRD showed a
median of 0.34% residual CLL cells (range 0–4.3%), with undetectable
CLL in two cases. None achieved a molecular CR.
Survival endpoints
The median follow-up of the ITT population was 34.2 months (range
3.0–43.5). The over 3-year PFS and EFS rates were 42.7% (95% CI, 27.3–
57.4%) and 38.2% (95% CI, 24.4–51.9%), respectively (Fig. 2a,b). The
median PFS and EFS were 34.7 (95% CI, 33.1–39.5) and 34.5 months
(95% CI, 25.2–38.2), respectively. The median OS was not reached.
Induction safety
CLB was used at 56 mg/m2 for 8 cycles (total dose: 448 mg/m2).
CLB dose reduction occurred in 51/657 cycles (7.8%), mostly for tox-
icity (40 cycles, 6.1%) and in 7/103 (6.7%), 18/210 (8.5%), 10/168
(5.9%), 14/136 (10.2%), and 2/40 cycles (5.0%) for patients aged 60–
64, 65–69, 70–74, 75–79, and 80 years, respectively.
In the safety population (N5 97), 76 patients (78.4%) had at least
one AE during induction: 84.6% in patients aged 60–64 years, 75%
aged 65–69, 80.7% aged 70–74, 70.0% aged 75–79, and 90.0% aged
80. Thirty-three of ninety-seven patients (34%) experienced general
disorders, the most frequent being pyrexia (12.4%), infusion-related
reaction (6.2%), fatigue (5.2%), asthenia (4.1%), and chest pain and
influenza-like symptoms (3.1%). Nineteen serious AEs (SAE)
occurred in seventeen patients (17.5%) during induction: 30.7% aged
60–64 years, 14.2% aged 65–69, 15.3% aged 70–74, 5% aged 75–79,
and 40% aged 80. The most common was anemia. Of them, five
were CLB-related (herpes zoster infection, erythematous rash, lumbar
pain, anemia, and fever of unknown origin) and three CLB-R-related
(pleural effusion, anemia, and neutropenia). One fatal SAE during
induction (renal failure and paralytic ileus) was not considered
TABLE I. Patients Characteristics at Baseline (ITT Population) and at Randomizationa
Characteristic
ITT Rituximab Observation
Patients, n or
n/N (N585) Patients, %
Patients, n or
n/N (N534) Patients, %
Patients, n or
n/N (N532) Patients, %
Age, years
60–64 13 15.3 6 17.6 5 15.6
65–69 27 31.8 13 38.2 10 31.3
70–74 24 28.2 7 20.6 10 31.3
75–79 17 20.0 7 20.6 6 18.8
80 4 4.7 1 2.9 1 3.1
Sex
Female 27 31.8 10 29.4 9 28.1
Male 58 68.2 24 70.6 23 71.9
B symptoms 24 28.2 8 23.5 9 28.1
Raised LDH 26/82 31.7 10/33 30.3 9/30 30.0
Lymphadenopathy 76 89.4 30 88.2 27 84.4
Splenomegaly 46 54.1 21 61.8 17 53.1
Hepatomegaly 14 16.5 4 11.8 8 25.0
ECOG performance status
0 75 88.2 33 97.1 27 84.4
1 7 8.2 0 0.0 3 9.4
>1 3 3.5 1 2.9 2 6.3
Binet stage
A 22 25.9 6 17.6 12 37.5
B 49 57.6 21 61.8 17 53.1
C 14 16.5 7 20.6 3 9.4
Comorbiditiesb
Cardiovascular 32 37.6 15 44.1 11 34.4
Endocrine and metabolic 20 23.5 8 23.5 8 25.0
Genitourinary 8 9.4 4 11.8 3 9.4
Psychiatric disease 5 5.9 3 8.8 0 0.0
Serum parameters
b-2M (>2 mg/L) 47/52 90.4 17/18 94.4 20/23 87.0
sCD23 (>70 UI/L) 75/78 96.2 31/31 100.0 29/31 93.5
TK (>7.1 U/L) 68/79 86.1 27/32 84.4 26/30 86.7
CD19/CD381 (20%) 34/83 41.0 14/33 42.4 13 40.6
ZAP-701 (20%) 63/83 75.9 26/33 78.8 21 65.6
IGHV unmutated 47/81 58.0 20/33 60.6 16/31 51.6
Hierarchical FISH-based chromosomal abnormalities
TP53 disruptionc 5/83 6.0 1/33 3.0 2 6.3
11q2 15/83 18.1 8/33 24.2 5 15.6
Trisomy 12 17/83 20.5 8/33 24.2 5 15.6
13q2 only 25/83 30.1 9/33 27.3 11 34.4
No abnormalities 21/83 25.3 7/33 21.2 9 28.1
Novel gene mutations
NOTCH1 12/82 14.6 3/33 9.1 6 18.7
SF3B1 11/82 13.4 4/33 12.1 4 12.5
BIRC3 disruptiond 8/82 9.8 5/33 15.1 2 6.2
ECOG5Eastern Cooperative Oncology Group; FISH5 fluorescence in situ hybridization; ITT5 intent-to-treat; TK5 thymidine kinase.
a Percentages are calculated on subject with sample performed and evaluable for each parameter.
b Patients with at least one comorbidity on the listed system. Comorbidities were assessed on the base of clinical charts and investigator’s judgment.
c TP53 disruption includes four patients with 17p2 and one patient with TP53 mutation without deletion.
d BIRC3 disruption includes patients with BIRC3 mutation and/or deletion.
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treatment related. Eight other deaths occurred after induction inter-
ruption: three from disease progression/relapse, one each from
pulmonary infection, spinocellular carcinoma, anaplastic oligoastrocy-
toma, respectively, and two from unknown causes.
Maintenance
Among the 66 randomized patients (4 CR/CRi and 30 PR/nPR in
the R arm, 12 CR/CRi and 20 PR in the observation arm), the OR
rate after maintenance was 55.9% (95% CI, 39.19–72.57%) in the R
arm and 34.4% (95% CI, 17.92–50.83%) in the observation arm,
respectively (P5 0.079); the CR and PR rate were 29.4% and 26.4%
in the R arm, and 18.7% and 12.5% in the observation arm, respec-
tively. Notably, among the 50 PR/nPR patients randomized after
induction, the proportion of responders to the R arm (17/30, 56.7%;
9 CR, 30%, 8 PR, 26.7%) was significantly higher than in the observa-
tion arm (5/20, 25%; 1 CR, 5%, 4 PR, 20%) (P5 0.027).
At R maintenance completion, 5/10 CR were evaluated for MRD: one
proved MRD2 in the PB and BM both immunophenotypically and
molecularly, two were MRD2 by flow in the PB and MRD1 in the BM;
two were MRD1 in both compartments. All of them were in PR after
induction (four PR, one nPR). At completion of the observation arm,
none of the six CR patients was MRD2: four CR with MRD1 after
induction experienced a MRD level increase, one MRD2 CR after induc-
tion became MRD1, one PR after induction achieved a MRD1 CR.
In the randomized population, the median follow-up was 34.9
months (34.4 and 35.2 months for R and observation arm, respec-
tively). The over 3-year PFS and median PFS rates were 48.6% and
38.2 months for R arm and 31.8% and 34.7 months for observation
arm, respectively. There was a trend towards a longer PFS for patients
receiving R maintenance (P5 0.07) (Fig. 2c).
In the R maintenance arm, 73.5% patients had at least one AE
compared to 56.3% in the observation arm, with no significant differ-
ence (P5 0.141); no differential distribution of AE was recorded
according to age. No difference in neutropenia (P5 0.101) or infec-
tions was recorded between the two arms (Table II). Ten SAE
occurred in eight patients (12.1%) during maintenance, with an equal
distribution according to arm and only one was R treatment-related
(neutropenia). No fatal SAE occurred during maintenance; three
patients (one in the R arm for lymphoma, two in the observation
arm for disease progression/relapse and second tumor, respectively)
died after maintenance interruption.
Biologic characteristics and patients’ outcome
Univariate analysis in the population with response assessment
(N5 77) evaluated the impact of prognostic factors on OR (Support-
ing Information Table SI) and CR (Supporting Information Table
SII) achievement after induction and on PFS.
Only TP53 disruption and a new model including complex karyo-
type within the high-risk FISH category (17p2 and 11q2) were sig-
nificantly associated to a poor response (each P5 0.022). The latter
also predicted CR achievement (P5 0.0225). Contrariwise, 11q2 was
not associated to a poor response (P5 0.403): 13/15 patients (86.7%)
achieved a response, including 3 CR and 10 PR.
Immunoglobulin heavy chain variable region gene (IGHV) muta-
tions were the only significant predictor of PFS (P5 0.0011), with
unmutated CLL having a 6.12 (2.070–18.077) higher risk of progres-
sion than mutated CLL.
Univariate analysis on the randomized population (N5 66) showed
a significant difference in OR according to the IGHV mutation status
in the observation arm (OR, 60% for mutated IGHV CLL vs. 12.5% for
IGHV unmutated cases, P5 0.009) but not in the R arm (OR, 69.2%
for mutated IGHV CLL vs. 45.0% for unmutated IGHV cases,
P5 0.284), and according to the maintenance arm among unmutated
IGHV patients (P5 0.067) but not among mutated IGHV CLL
(P5 0.705). Consistently, a significantly different PFS within unmu-
tated IGHV patients according to the maintenance arm was found
(P5 0.012): the median PFS was 38.2 months (95% CI, 30.4–39.5) and
22.8 (95% CI, 20.1–33.1), respectively, for R and the observation arm.
A similar trend was observed for 112 CLL (OR, 66.67% in the R
arm vs. 14.3% in the observation arm, P5 0.06). On multivariate
analysis on the randomized population, unmutated IGHV independ-
ently predicted a significantly shorter PFS (P5 0.0048) and TTNT
(P5 0.0189). Maintenance arm and 13q2 showed a trend towards
significance for PFS (P5 0.0747 and P5 0.0512, respectively).
Novel gene mutations and patients’ outcome
Novel gene mutations were evaluable in 74 cases with response
assessment. Nine patients were NOTCH1 mutated: all responded to
induction and 44% achieved a CR, with no significant difference with
wild-type cases. Nine showed SF3B1 mutations: 8/9 responded, not
differently from wild-type cases; however, only 1/9 (11%) SF3B1
mutated cases obtained a CR, as opposed to 14/65 (21.5%) wild-type
cases. Similarly, 7/8 BIRC3 mutated/deleted patients had an OR, with
only 1 CR. For each mutation, PFS was assessed stratifying patients
according to the presence of: (1) one of the novel mutations; (2)
TP53 disruption; (3) no mutations/disruptions. Only SF3B1 mutations
showed a trend towards a shorter PFS (P5 0.0761).
Neither in the R or observation arm, a significant impact on
response was recorded according to the presence of mutations in 65
evaluable cases.
GEP and response to therapy
The GEP of 62 patients (CR/CRi5 16, PR5 41, no response
[NR]5 5, including SD5 2 and PD5 3) was analyzed: samples did
Figure 2. Survival endpoints. (a) Progression-free survival (PFS) of the ITT population. (b) Event-free survival (EFS) of the ITT population. (c) Progression-
free survival (PFS) of the randomized population according to maintenance arm. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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not cluster according to their clinical responses either by unsupervised
analysis or when comparing the three groups by ANOVA (not shown).
Contrariwise, the ANOVA analysis of CR versus NR patients (Sup-
porting Information Fig. S1A) highlighted a homogeneous signature in
the NR group, where two patients with concomitant 17p2 and TP53
mutation displayed the strongest signature. DAVID functional analysis
revealed an overrepresentation of apoptotic (P< 0.0001) and anti-
apoptotic pathways (P< 0.0001) (Supporting Information Fig. S1B).
Anti-apoptotic and pro-proliferative genes were more represented
in the NR group, with the upmodulation of the Ras and Rho path-
ways; indeed, the upregulation of KRAS, EP300, and NRAS (Support-
ing Information Table SIII) was confirmed by quantitative PCR,
particularly in the PD patients (not shown). NR patients also showed
a significant downmodulation of the CD20 transcript, that correlated
with CD20 mean fluorescence intensity (Pearson correlation coef-
ficient5 0.57). However, the correlation of the latter with response
did not reach statistical significance (Supporting Information Fig. S2).
Among PR patients after induction who received R maintenance
(n5 21), GEP analysis showed a clusterization according to their clin-
ical response after maintenance, with a distinctive signature for the
NR patients, again including the upmodulation of anti-apoptotic
genes (Supporting Information Fig. S1C).
 Discussion
The primary objective of this study was to evaluate the efficacy of
CLB-R induction on OR achievement in elderly CLL patients. The
trial provided very satisfactory results: the response rate—82.4% OR,
including 16.5% CR and 2.4% CRi, with cytometric MRD2 in 14%
of CR cases—compares favorably with the 31–55% OR rates of trials
using single-agent CLB at comparable doses [7,8,23], the 72% OR of
the LRF CLL4 trial, using higher doses of single-agent CLB [6] and is
supported by a similar British trial using CLB-R (OR 82%) [11]. Fur-
thermore, in our study, PFS (34.7 months) is higher than that
reported in trials using single-agent CLB (8.3–18 months) [6–
8,12,23]. A preliminary analysis of the German CLL11 trial, compar-
ing CLB alone, obinutuzumab1CLB, and CLB-R in untreated CLL
patients with comorbidities, has been released [12]. The CLB-R arm
provides inferior results (OR 65%, CR 7%, PFS 15.2 months) com-
pared to ours, probably due to the lower CLB dosage/cycle and num-
ber of cycles. Interestingly, our OR and EFS results are also not
inferior to those achieved by bendamustine plus R, although with less
CR, and with a remarkably lower grade 3–4 hematologic toxicity [24].
Even though these comparisons have strong limitations due to different
age inclusion criteria, CLB dosage, and treatment duration [9], it is
worth noting that our study included patients with a median age of 70
years and is the only one including the maintenance with R [25–27].
At variance from fludarabine-based regimens, CLB-R was well tol-
erated: over three-quarter of patients completed all 8 induction cycles,
regardless of age. CLB dose reduction was needed in 7.8% of cycles,
due to toxicity in 6.1%.
In our study, AEs were generally hematologic, with neutropenia
being the most common and affecting approximately one-third of
patients in induction. Infections occurred in 15.5% of patients,
although rarely of grade 3–4 (1%). Thus, CLB-R toxicity compares
favorably with other trials using CLB alone or with R [6–8,11,23].
Infusion-related side effects were limited.
The role of maintenance in CLL is still an open issue, so far inves-
tigated by the use of monoclonal antibodies or lenalidomide. As in
other chronic B-cell malignancies, the use of R after induction chem-
otherapy suggests a benefit in sustaining the response duration in
CLL patients [28–31]. Most of the published studies used R after
fludarabine-based regimens; the most recent one after FCR plus
mitoxantrone, with a remarkable efficacy but a relevant hematologicTA
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and infectious toxicity [31]. Our study is the first to explore R main-
tenance after CLB-R induction. Although we could not formally dem-
onstrate a clear advantage of R maintenance in responders after CLB-
R induction, as maintenance was not the primary objective of the
study, a better PFS was recorded compared to the control arm. In
particular, PR/nPR patients after induction completion benefitted the
most from R maintenance in terms of response improvement. More-
over, R maintenance determined a MRD clearing in induction res-
ponders in contrast to the observation arm, where MRD levels
increased in all patients.
Remarkably, under R maintenance AE, SAE, neutropenia, or infec-
tions were as frequent as in the observation arm. Infections were the
most common AE during maintenance, affecting one-fourth of
patients, although never of grade 3–4. This supports the feasibility of
maintenance strategies in elderly and/or unfit patients provided that
the induction is not intensive and/or immunosuppressive [31].
Among several biologic markers, most had a limited value in pre-
dicting response to CLB-R, with the exception of genetic abnormal-
ities. 17p2/TP53 mutations and complex karyotype were significantly
associated to a poor response and CR rate. Contrariwise, our data
suggest that an induction therapy combining R and an alkylating
agent may be beneficial for 11q2 patients who are elderly and/or
unfit for FCR [32].
Neither NOTCH1, SF3B1, or BIRC3 mutations impacted on OR
after induction, in line with other reports [33,34]; however, SF3B1
mutations and BIRC3 disruption were rarely detected in CR patients.
The only biologic marker significantly associated to a worse PFS
was an unmutated IGHV status, although this did not impact on
response to induction. Unmutated IGHV independently predicted a
shorter PFS and TTNT also among randomized patients. However,
the significant difference in response and PFS according to the IGHV
mutational status found in the observation arm but not in the R arm
suggests a benefit for unmutated IGHV in receiving R maintenance.
GEP may be useful in predicting response to induction and to R
maintenance. NR patients in induction displayed a distinct signature
from that of CR patients, with the concomitant downmodulation of
pro-apoptotic and upmodulation of anti-apoptotic and pro-
proliferative genes. Of interest is the overexpression of KRAS and
NRAS [35], and the downmodulation of the CD20 gene in NR
patients. The latter observation, in line with in vitro [36] and in vivo
data [31], suggests that higher doses or new anti-CD20 antibodies
may be beneficial in biologically identified subsets of patients.
In conclusion, this study shows that: (i) CLB-R induction is an
active first-line treatment for elderly CLL patients, regardless of age
and disease stage; (ii) the toxicity is limited and manageable, regard-
less of age; (iii) PFS is promising and higher than that reported with
CLB alone; (iv) CLB-R seems active also among 11q2 patients; (v)
NR patients may be identified by TP53 abnormalities/complex karyo-
type, a distinctive GEP, and low CD20 gene expression; (vi) IGHV
mutations strongly influence PFS; (vii) low CR rates are recorded
among SF3B1 mutated and BIRC3 disrupted cases. Moreover, we sug-
gest that R maintenance is doable in elderly CLL patients and tends
to improve PFS in patients responders to a CLB-R induction, not
increasing toxicity compared to observation in terms of AE, SAE,
neutropenia, or infections. It seems beneficial mostly in PR/nPR
patients after induction in terms of response improvement and in
unmutated IGHV patients. Therefore, we support the need of pro-
spective phase III clinical trials to conclusively define the role of
maintenance in maintaining response and prolonging survival also in
elderly CLL patients. Rituximab, ofatumumab, and obinutuzumab are
the candidates that deserve a comparison in this context.
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